Investor Presentaiton

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 Cosentyx LCM canakinumab LCM aflibercept BioS Beovu LCM Atectura LCM secukinumab, AIN457 ACZ885 SOK583 PSA IV Adjuvant NSCLC Neovascular age-related macular degeneration brolucizumab, RTH258 Diabetic retinopathy indacaterol + mometasone, QMF149 Asthma, pediatrics ≥2026 Kesimpta³ ofatumumab LCM Mayzent³ LCM siponimod, BAF312 Multiple sclerosis, pediatrics Multiple sclerosis, pediatrics Cosentyx LCM Cosentyx LCM Adakveo LCM Cosentyx LCM Aimovig LCM Kymriah LCM Piqray LCM secukinumab, AIN457 secukinumab, AIN457 SEG101 secukinumab, AIN457 erenumab, AMG334 tisagenlecleucel, CTL019 alpelisib, BYL719 Hidradenitis suppurativa axSpA IV Sickle cell disease, pediatrics GCA Pediatric Migraine 1L high risk ALL, pediatrics & young adults TNBC Entresto EU1 LCM denosumab BioS Coartem LCM Cosentyx LCM Cosentyx LCM Leqvio LCM Rydapt LCM sacubitril/valsartan, LCZ696 GP2411 Pediatric CHF anti RANKL mAb artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg secukinumab, AIN457 Lichen Planus secukinumab. AIN457 Lupus Nephritis KJX839 midostaurin, PKC412 CVRR-LDLC Acute myeloid leukemia, pediatrics Tafinlar + Mekinist LCM Kisqali LCM Jakavi LCM Leqvio LCM dabrafenib + trametinib, DRB436 ribociclib, LEE011 ruxolitinib, INC424 KJX839 HGG/LGG - Pediatrics. HR+/HER2- BC (adj) Pediatrics Acute GVHD Ped Hyperlipidemia Xolair LCM Lutathera LCM Jakavi LCM Piqray LCM omalizumab, IGE025 177Lu-oxodotreotide² ruxolitinib, INC424 alpelisib, BYL719 Auto-injector GEP-NET 1L G3 Pediatrics Chronic GVHD HER2+ adv BC Piqray LCM Promacta LCM alpelisib, BYL719 eltrombopag, ETB115 Ovarian cancer Radiation sickness syndrome Xolair LCM Zolgensma LCM omalizumab, IGE025 AVXS-101 OAV101 Food allergy SMA IT 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). 44 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation